Halving heart failure outcomes by finerenone-mediated type 2 diabetes prevention
- PMID: 39818227
- DOI: 10.1016/S2213-8587(24)00317-6
Halving heart failure outcomes by finerenone-mediated type 2 diabetes prevention
Conflict of interest statement
HCG reports holding the McMaster–Sanofi Population Health Institute Chair in Diabetes Research and Care; research grants from Eli Lilly, Novo Nordisk, and Hanmi; continuing education grants from Eli Lilly, Abbott, Sanofi, Novo Nordisk, and Boehringer Ingelheim; honoraria for speaking from AstraZeneca, Eli Lilly, Novo Nordisk, Zuellig, Sanofi, Carbon Brand, and Jiangsu Hanson; and consulting fees from Abbott, Bayer, Eli Lilly, Novo Nordisk, Pfizer, Sanofi, and Hanmi. KM reports consulting fees from Novo Nordisk; honoraria for lectures, presentations, or speakers bureaus from Novo Nordisk, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Sanofi, Lifescan, Abbott, and Bayer; and participation on advisory boards for Novo Nordisk, Sanofi, and Amarin.
Comment on
-
Finerenone and new-onset diabetes in heart failure: a prespecified analysis of the FINEARTS-HF trial.Lancet Diabetes Endocrinol. 2025 Feb;13(2):107-118. doi: 10.1016/S2213-8587(24)00309-7. Epub 2025 Jan 13. Lancet Diabetes Endocrinol. 2025. PMID: 39818225 Clinical Trial.
Publication types
LinkOut - more resources
Full Text Sources